Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Bernstein analyst Jeffrey Walch maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $756 to $812.
Bernstein analyst Jeffrey Walch maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $756 to $812.